442-N RNA primed SMAR-TTM cells against multiple driver mutations, all HLA’s, designed for first line therapy

Abstract

BackgroundSuccess of immune checkpoint inhibitors, e.g., anti-PD1 antibodies have revolutionized cancer immunotherapy by demonstrating that a patient’s own T-cells recognize and treat cancer. The efficacy of PD-1 blockade is driven...